2 hours Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Rating Reaffirmed by Canaccord Genuity Group MarketBeat
Canaccord Genuity Group reaffirmed a “buy” rating and issued a $38.00 target price on shares of Rocket Pharmaceuticals in a research note on Monday.
Nasdaq 100 · Pharmaceuticals · Science